News for Heron Therapeutics, Inc. (HRTX)

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

Heron Therapeutics (HRTX), a biotechnology company focused on developing medical solutions, has received a new "Buy" rating from HC Wainwright & Co. as of June

An analyst at H.C. Wainwright, Brandon Folkes, has initiated coverage on Heron Therapeutics (HRTX) with a Buy rating and set a price target of $6. Heron Therape

Heron Therapeutics' Q1'25 earnings show Cinvanti leading, Zynrelef's 60% sales growth, raised EBITDA guidance & future potential. Learn more on HRTX stock here.

Total Net Revenues: Approximately $39 million for Q1 2025.Adjusted EBITDA: Record quarterly adjusted EBITDA of $6.2 million.Net Income: $2.6 million for Q1 202

May 06, 2025 / 12:00PM GMTOperator Good day and thank you for standing by. Welcome to the Heron Therapeutics' Q1 2025 conference call. (Operator Instructions) P

Key Highlights: Heron Therapeutics (HRTX) settles a patent dispute with Mylan, with generics release set for June 2032. The settlement announcement boost

Heron Therapeutics, Inc. (NASDAQ:HRTX) Q1 2025 Earnings Conference Call May 6, 2025 8:00 AM ETCompany ParticipantsMelissa Jarel - Executive Director,...

VANCOUVER, Washington, May 06, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. ( CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CC

While the top- and bottom-line numbers for Heron Therapeutics (HRTX) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

The following slide deck was published by Heron Therapeutics, Inc.

Net Revenue: Achieved $38.9 million, surpassing the estimated $37.42 million.Earnings Per Share (EPS): Reported at $0.01, exceeding the estimated -$0.01.Adjust

Heron Therapeutics (HRTX) has reached a settlement with Mylan Pharmaceuticals, a subsidiary of Viatris, to resolve ongoing patent disputes concerning its inject

Heron Therapeutics, Inc. (HRTX) reported impressive first-quarter results, with revenue hitting $38.9 million, surpassing market expectations of $37.42 million.

PR NewswireCARY, N.C., May 6, 2025 Generated Q1 2025 Net Revenue of $38.9 millionDelivered record Q1 2025 Adjusted EBITDA of $6.2 millionReached settlement

PR NewswireCARY, N.C., May 6, 2025 ”” Company Grants Mylan a License to Market Generic CINVANTI® and APONVIE® Beginning in June 2032 ””CARY, N.C., May

Mark Hensley appointed as Chief Operating Officer at Heron Therapeutics (HRTX). Hensley brings over 15 years of pharmaceutical industry experience, prev

PR NewswireCARY, N.C., April 28, 2025 CARY, N.C., April 28, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a comm

PR NewswireCARY, N.C., April 22, 2025 CARY, N.C., April 22, 2025 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX) ("Heron" or the "Company"), a comm